Connect with us

Business

Researchers may have found a drug that could delay Alzheimer’s symptoms. It’s funding is caught up in Trump administration delays

Published

on



An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing research now caught up in Trump administration funding delays.

The early results—a scientific first—were published Wednesday even as study participants worried that politics could cut their access to a possible lifeline.

“It’s still a study but it has given me an extension to my life that I never banked on having,” said Jake Heinrichs of New York City.

Now 50, Heinrichs has been treated in that study for more than a decade and remains symptom-free despite inheriting an Alzheimer’s-causing gene that killed his father and brother around the same age.

If blocked funding stops Heinrichs’ doses, “how much time do we have?” asked his wife, Rachel Chavkin. “This trial is life.”

Two drugs sold in the U.S. can modestly slow worsening of early-stage Alzheimer’s by clearing the brain of one of its hallmarks, a sticky gunk called amyloid. But until now, there haven’t been hints that removing amyloid far earlier—many years before the first symptoms appear—just might postpone the disease.

The research led by Washington University in St. Louis involves families that pass down rare gene mutations almost guaranteeing they’ll develop symptoms at the same age their affected relatives did – information that helps scientists tell if treatments are having any effect.

The new findings center on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset, researchers reported Wednesday in the journal Lancet Neurology.

Despite the study’s small size, “it’s incredibly important,” said Northwestern University neuroscientist David Gate, who wasn’t involved with the research.

Now participants have been switched from an earlier experimental drug to Leqembi, an IV treatment approved in the U.S., to try to answer the obvious next question.

“What we want to determine over the next five years is how strong is the protection,” said Washington University’s Dr. Randall Bateman, who directs the Dominantly Inherited Alzheimer’s Network of studies involving families with these rare genes. “Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

Here’s the worry: Bateman raised money to start that confirmatory study while seeking National Institutes of Health funding for the full project but his grant has been delayed as required reviews were canceled. It’s one example of how millions of dollars in research have been stalled as NIH grapples with funding restrictions and mass firings.

At the same time researchers wonder if NIH will shift focus away from amyloid research after comments by Dr. Jay Bhattacharya, nominated as the agency’s new director.

“One of the reasons I think that we have not made progress in Alzheimer’s, as much as we ought to have, is because the NIH has not supported a sufficiently wide range of hypotheses,” Bhattacharya told senators, responding to one who brought up an example of earlier science misconduct unrelated to current research.

Scientists don’t know exactly what causes Alzheimer’s, a mind-destroying disease that affects nearly 7 million Americans, mostly late in life. What’s clear is that silent changes occur in the brain at least two decades before the first symptoms — and that sticky amyloid is a major contributor. At some point amyloid buildup appears to trigger a protein named tau to begin killing neurons, which drives cognitive decline.

Tau-fighting drugs now are being tested. Researchers also are studying other factors including inflammation, the brain’s immune cells and certain viruses.

NIH’s focus expanded as researchers found more potential culprits. In 2013, NIH’s National Institute on Aging funded 14 trials of possible Alzheimer’s drugs, over a third targeting amyloid. By last fall, there were 68 drug trials and about 18% targeted amyloid.

Northwestern’s Gate counts himself among scientists who “think amyloid isn’t everything,” but said nothing has invalidated the amyloid hypothesis. He recently used brain tissue preserved from an old amyloid study to learn how immune cells called microglia can clear those plaques and then switch to helping the brain heal, possible clues for improving today’s modest therapies.

For now, amyloid clearly is implicated somehow and families with Alzheimer’s-causing genes are helping answer a critical question for anyone at risk: Can blocking amyloid buildup really stave off symptoms? Without NIH funding, Bateman said, that opportunity will be lost.

“It’s absolutely insane,” said longtime study participant June Ward, who lives near Asheville, North Carolina, and plans to ask friends to complain to lawmakers.

Ward turns 64 in June and is healthy, two years older than when her mother’s symptoms appeared. “It is exciting to think about the possibility that Alzheimer’s disease might not be what gets me,” she said.

In New York, Heinrichs said he has hope that his 3-year-old son won’t “experience the stress and sorrow that I lived through as a young man to watch my father fade away.”

“We need the NIH to be not politicized,” added Chavkin, his wife. “It’s just about keeping people alive or helping them live better. And in this case, it’s helping my husband survive.”

For more on Alzheimer’s:

This story was originally featured on Fortune.com



Source link

Continue Reading

Business

Trump’s reciprocal tariffs are ‘ripping up trade’ after decades of precedent. Here’s how tariffs got so lopsided in the first place

Published

on



President Donald Trump is taking a blowtorch to the rules that have governed world trade for decades. The “reciprocal’’ tariffs that he is expected to announce Wednesday are likely to create chaos for global businesses and conflict with America’s allies and adversaries alike.

Since the 1960s, tariffs — or import taxes — have emerged from negotiations between dozens of countries. Trump wants to seize the process.

“Obviously, it disrupts the way that things have been done for a very long time,’’ said Richard Mojica, a trade attorney at Miller & Chevalier. “Trump is throwing that out the window … Clearly this is ripping up trade. There are going to have to be adjustments all over the place.’’

Pointing to America’s massive and persistent trade deficits – not since 1975 has the U.S. sold the rest of the world more than it’s bought — Trump charges that the playing field is tilted against U.S. companies. A big reason for that, he and his advisers say, is because other countries usually tax American exports at a higher rate than America taxes theirs.

Trump has a fix: He’s raising U.S. tariffs to match what other countries charge.

The president is an unabashed tariff supporter. He used them liberally in his first term and is deploying them even more aggressively in his second. Since returning to the White House, he has slapped 20% tariffs on China, unveiled a 25% tax on imported cars and trucks set to take effect Thursday, effectively raised U.S. taxes on foreign steel and aluminum and imposed levies on some goods from Canada and Mexico, which he may expand this week.

Economists don’t share Trump’s enthusiasm for tariffs. They’re a tax on importers that usually get passed on to consumers. But it’s possible that Trump’s reciprocal tariff threat could bring other countries to the table and get them to lower their own import taxes.

“It could be win-win,” said Christine McDaniel, a former U.S. trade official now at George Mason University’s Mercatus Center. “It’s in other countries’ interests to reduce those tariffs.”

She noted that India has already cut tariffs on items from motorcycles to luxury cars and agreed to ramp up purchases of U.S. energy.

What are reciprocal tariffs and how do they work?

They sound simple: The United States would raise its tariff on foreign goods to match what other countries impose on U.S. products.

“If they charge us, we charge them,’’ the president said in February. “If they’re at 25, we’re at 25. If they’re at 10, we’re at 10. And if they’re much higher than 25, that’s what we are too.’’

But the White House didn’t reveal many details. It has directed Commerce Secretary Howard Lutnick to deliver a report this week about how the new tariffs would actually work.

Among the outstanding questions, noted Antonio Rivera, a partner at ArentFox Schiff and a former attorney with U.S. Customs and Border Protection, is whether the U.S. is going to look at the thousands of items in the tariff code – from motorcycles to mangos — and try to level the tariff rates out one by one, country by country. Or whether it will look more broadly at each country’s average tariff and how it compares to America. Or something else entirely.

“It’s just a very, very chaotic environment,” said Stephen Lamar, president and CEO of the American Apparel & Footwear Association. “It’s hard to plan in any sort of long-term, sustainable way.’’

How did tariffs get so lopsided?

America’s tariffs are generally lower than those of its trading partners. After World War II, the United States pushed for other countries to lower trade barriers and tariffs, seeing free trade as a way to promote peace, prosperity and American exports around the world. And it mostly practiced what it preached, generally keeping its own tariffs low and giving American consumers access to inexpensive foreign goods.

Trump has broken with the old free trade consensus, saying unfair foreign competition has hurt American manufacturers and devastated factory towns in the American heartland. During his first term, he slapped tariffs on foreign steel, aluminum, washing machines, solar panels and almost everything from China. Democratic President Joe Biden largely continued Trump’s protectionist policies.

The White House has cited several examples of especially lopsided tariffs: Brazil taxes ethanol imports, including America’s, at 18%, but the U.S. tariff on ethanol is just 2.5%. Likewise, India taxes foreign motorcycles at 100%, America just 2.4%.

Does this mean the U.S. been taken advantage of?

The higher foreign tariffs that Trump complains about weren’t sneakily adopted by foreign countries. The United States agreed to them after years of complex negotiations known as the Uruguay Round, which ended in a trade pact involving 123 countries.

As part of the deal, the countries could set their own tariffs on different products – but under the “most favored nation’’ approach, they couldn’t charge one country more than they charged another. So the high tariffs Trump complains about aren’t aimed at the United States alone. They hit everybody.

Trump’s grievances against U.S. trading partners also come at an odd time. The United States, running on strong consumer spending and healthy improvements in productivity, is outperforming the world’s other advanced economies. The U.S. economy grew nearly 9% from just before COVID-19 hit through the middle of last year — compared with just 5.5% for Canada and just 1.9% for the European Union. Germany’s economy shrank 2% during that time.

Trump’s plan goes beyond foreign countries’ tariffs

Not satisfied with scrambling the tariff code, Trump is also going after other foreign practices he sees as unfair barriers to American exports. These include subsidies that give homegrown producers an advantage over U.S. exports; ostensible health rules that are used to keep out foreign products; and loose regulations that encourage the theft of trade secrets and other intellectual property.

Figuring out an import tax that offsets the damage from those practices will add another level of complexity to Trump’s reciprocal tariff scheme.

The Trump team is also picking a fight with the European Union and other trading partners over so-called value-added taxes. Known as VATs, these levies are essentially a sales tax on products that are consumed within a country’s borders. Trump and his advisers consider VATs a tariff because they apply to U.S. exports.

Yet most economists disagree, for a simple reason: VATs are applied to domestic and imported products alike, so they don’t specifically target foreign goods and haven’t traditionally been seen as a trade barrier.

And there’s a bigger problem: VATs are huge revenue raisers for European governments. “There is no way most countries can negotiate over their VAT … as it is a critical part of their revenue base,’’ Brad Setser, senior fellow at the Council on Foreign Relations, posted on X.

Paul Ashworth, chief North America economist for Capital Economics, says that the top 15 countries that export to the U.S. have average VATs topping 14%, as well as duties of 6%. That would mean U.S. retaliatory tariffs could reach 20% — much higher than Trump’s campaign proposal of universal 10% duties.

Tariffs and the trade deficit

Trump and some of his advisers argue that steeper tariffs would help reverse the United States’ long-standing trade deficits.

But tariffs haven’t proven successful at narrowing the trade gap: Despite the Trump-Biden import taxes, the deficit rose last year to $918 billion, second-highest on record.

The deficit, economists say, is a result of the unique features of the U.S. economy. Because the federal government runs a huge deficit, and American consumers like to spend so much, U.S. consumption and investment far outpaces savings. As a result, a chunk of that demand goes to overseas goods and services.

The U.S. covers the cost of the trade gap by essentially borrowing from overseas, in part by selling treasury securities and other assets.

“The trade deficit is really a macroeconomic imbalance,” said Kimberly Clausing, a UCLA economist and former Treasury official. “It comes from this lack of desire to save and this lack of desire to tax. Until you fix those things, we’ll run a trade imbalance.”

This story was originally featured on Fortune.com



Source link

Continue Reading

Business

Three mystery whales have each spent $10 billion–plus on Nvidia’s AI chips so far this year

Published

on



AI microchip supplier Nvidia, the world’s most valuable company by market cap, remains heavily dependent on a few anonymous customers that collectively contribute tens of billions of dollars in revenue. 

The AI chip darling once again warned investors in its quarterly 10-Q filing to the SEC that it has key accounts so crucial that their orders each crossed the threshold of 10% of Nvidia’s global consolidated turnover. 

An elite trio of particularly deep-pocketed customers, for example, individually purchased between $10 billion and $11 billion worth of goods and services across the first nine months that ended in late October.

Fortunately for Nvidia investors, this won’t change anytime soon. Mandeep Singh, global head of technology research at Bloomberg Intelligence, says he believes founder and CEO Jensen Huang’s prediction that spending will not stop.  

“The data-center training market could hit $1 trillion without any real pullback,” he says. By that point, Nvidia’s share will almost certainly drop markedly from its current 90%. But it could still be in the hundreds of billions of dollars in revenue annually.

Nvidia remains supply constrained

Outside of defense contractors living off the Pentagon, it’s highly unusual that a company has such a concentration of risk among a handful of customers—let alone one poised to become the first worth the astronomical sum of $4 trillion.

Looking at Nvidia’s accounts on a strictly three-month basis, there were four anonymous whales that, in total, comprised nearly every second dollar of sales in the second fiscal quarter; this time at least one of them has dropped out since now only three still meet that criteria. 

Singh told Fortune the anonymous whales likely include Microsoft, Meta, and possibly Super Micro. But Nvidia declined to comment on the speculation.

Nvidia only refers to them as Customers A, B, and C, and all told they purchased a collective $12.6 billion in goods and services. This was more than a third of Nvidia’s overall $35.1 billion recorded for the fiscal third quarter through late October. 

Their share was also divided up equally with each accounting for 12%, suggesting they were likely receiving a maximum amount of chips allocated to them rather than as many as they might have ideally wanted. 

This would fit with comments from founder and CEO Jensen Huang that his company is supply constrained. Nvidia cannot simply pump out more chips, since it has outsourced wholesale fabrication of its industry-leading AI microchips to Taiwan’s TSMC and has no production facilities of its own.

Middlemen or end user?

Importantly, Nvidia’s designation of major anonymous customers as Customer A, Customer B, and so on is not fixed from one fiscal period to the next. They can and do change places, with Nvidia keeping their identity a trade secret for competitive reasons; no doubt these customers would not like their investors, employees, critics, activists, and rivals being able to see exactly how much money they spend on Nvidia chips.

For example, one party designated “Customer A” bought around $4.2 billion in goods and services over the past quarterly fiscal period. Yet it appears to have accounted for less in the past, since it does not exceed the 10% mark across the first nine months in total.

Meanwhile “Customer D” appears to have done the exact opposite, reducing purchases of Nvidia chips in the past fiscal quarter yet nevertheless representing 12% of turnover year to date.

Since their names are secret, it’s difficult to say whether they are middlemen like the troubled Super Micro Computer, which supplies data center hardware, or end users like Elon Musk’s xAI. The latter came out of nowhere, for example, to build up its new Memphis compute cluster in just three months’ time. 

Longer-term risks for Nvidia include the shift from training to inference chips

Ultimately, however, there are only a handful of companies with the capital to be able to compete in the AI race, as training large language models can be exorbitantly costly. Typically these are the cloud computing hyperscalers such as Microsoft.

Oracle, for example, recently announced plans to build a zettascale data center with over 131,000 Nvidia state-of-the-art Blackwell AI training chips, which would be more powerful than any individual site yet existing. 

It’s estimated the electricity needed to run such a massive compute cluster would be equivalent to the output capacity of nearly two dozen nuclear power plants.

Bloomberg Intelligence analyst Singh sees only a few longer-term risks for Nvidia. For one, some hyperscalers will likely reduce orders eventually, diluting its market share. One such likely candidate is Alphabet, which has its own training chips called TPUs.

Secondly, its dominance in training is not matched by inference, which runs generative AI models after they have already been trained. Here, the technical requirements are not nearly as state of the art, meaning there is much more competition, not just from rivals like AMD but also companies with their own custom silicon like Tesla. Eventually inference will be a much more meaningful business as more and more businesses utilize AI. 

“There are a lot of companies trying to focus on that inferencing opportunity, because you don’t need the highest-end GPU accelerator chip for that,” Singh said. 

Asked if this longer-term shift to inferencing was a bigger risk than eventually losing share in the market for training chips, he replied: “Absolutely.”

This story was originally featured on Fortune.com



Source link

Continue Reading

Business

Trump task force will probe $8.7 billion in funding for Harvard after Columbia bowed to federal demands

Published

on

Harvard University has become the latest target in the Trump administration’s approach to fight campus antisemitism, with the announcement of a new “comprehensive review” that could jeopardize billions of dollars for the Ivy League college.

A federal antisemitism task force is reviewing more than $255 million in contracts between Harvard and the federal government to make sure the school is following civil rights laws, the administration announced Monday. The government also will examine $8.7 billion in grant commitments to Harvard and its affiliates.

The same task force cut $400 million from Columbia University and threatened to slash billions more if it refused a list of demands from President Donald Trump’s administration. Columbia agreed to many of the changes this month, drawing praise from some Jewish groups and condemnation from free speech groups, who see it as a stunning intrusion by the federal government.

Dozens of other universities have been put on notice by the Trump administration that they could face similar treatment over allegations of antisemitism. The federal government is a major provider of revenue for American universities through grants for scientific research.

Education Secretary Linda McMahon said Harvard symbolizes the American Dream, but has jeopardized its reputation by “promoting divisive ideologies over free inquiry” and failing to protect students from antisemitism.

“Harvard can right these wrongs and restore itself to a campus dedicated to academic excellence and truth-seeking, where all students feel safe on its campus,” McMahon said in a statement.

Harvard did not immediately respond to messages seeking comment. The elite university is among more than 100 colleges and school systems facing investigations for antisemitism or Islamophobia following Hamas’ Oct. 7, 2023, attack against Israel. The Trump administration has promised tougher action than its predecessor, naming antisemitism as the top priority for civil rights investigations.

Monday’s announcement didn’t say whether the government had made any specific demands of Harvard. The Education Department, the Health and Human Services Department and the U.S. General Services Administration are leading the review of its contracts and grants.

Those agencies will determine whether orders to halt work should be issued for certain contracts between Harvard and the federal government, the government said. The task force is also ordering Harvard to submit a list of all contracts with the federal government, both directly with the school or through any of its affiliates.

“The Task Force will continue its efforts to root out anti-Semitism and to refocus our institutions of higher learning on the core values that undergird a liberal education,” said Sean Keveney, acting general counsel for Health and Human Services. “We are pleased that Harvard is willing to engage with us on these goals.”

Some of the nation’s most prestigious colleges have faced extraordinary scrutiny from Republicans in Congress following a wave of pro-Palestinian protests that started at Columbia and spread across the country last year. Presidents of several Ivy League schools were called before Congress over allegations that they allowed antisemitism to fester.

The hearings on Capitol Hill contributed to the resignation of presidents at HarvardColumbia and Penn. The interim president who took over at Columbia, Katrina Armstrong, resigned last week after the school agreed to the government’s demands.

Trump and other officials have accused the protesters of being “pro-Hamas.” Student activists say they oppose Israel’s military activity in Gaza.

Instead of going through a lengthy process that allows the Education Department to cut funding from schools that violate civil rights laws, the Trump administration has found quick leverage by pulling contracts and grants. The tactic is being challenged in a federal lawsuit brought by the American Association of University Professors and the American Federation of Teachers.

This story was originally featured on Fortune.com



Source link

Continue Reading

Trending

Copyright © Miami Select.